Navigation Links
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:12/9/2008

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary endpoints. Treatment with APD125 was well tolerated, and there were no reports of serious adverse events and no emerging safety findings as compared to placebo. Arena is finishing a complete analysis of the data, but does not anticipate any further development of APD125.

"While we are disappointed and anticipated a different result based on objective polysomnographic results from our previous studies, our priority remains the successful development of lorcaserin, our proprietary investigative treatment for obesity. We expect to announce lorcaserin results from BLOOM, our first pivotal Phase 3 clinical trial, around the end of March and to file a New Drug Application for lorcaserin by the end of 2009," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to the opportunity to review our lorcaserin program, as well as other programs, at our upcoming R&D Day on December 15."

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Critical Pharmaceuticals Enter Sustained Release hGH Arena
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
8. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015  SillaJen, Inc., a ... of oncolytic immunotherapy products for cancer, today announced ... the Annual Meeting of the American Association for ... murine adapted version of its lead product candidate, ... is an oncolytic immunotherapy designed to 1) rapidly ...
(Date:4/20/2015)... , April 20, 2015 The preclinical contract research ... testing of drugs and safety testing of medical devices, announces ... at this week,s workshop " Drug Transporters in ADME: From ... MD . The title of Dr. Hidalgo,s talk is ... a session entitled "Transporter Tools of the Future." ...
(Date:4/20/2015)... , April 20, 2015   Gateway ... Research and Training Institute today expanded its Naloxone: ... outpatient locations.  A $50,000 grant from the ... research project possible.  The yearlong ... to patients and their family members upon completion ...
Breaking Medicine Technology:SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 3Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 3
... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... , A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
... , EMERYVILLE, Calif., Dec. 4 ... it will host an investor teleconference and webcast. Principal ... and/or refractory multiple myeloma, as featured at the 51st American ... begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December ...
Cached Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2
(Date:4/20/2015)... Bronx, NY (PRWEB) April 20, 2015 The ... are introducing the community to Bella Diosa Laser Med Spa ... invited to a spa party on from 12–7 p.m. on ... The event will include drinks and refreshments. Participants will also ... Attendees will receive a free gift with any purchase, as ...
(Date:4/20/2015)... is a seemingly idyllic and tranquil island oasis in ... off the southeastern coast of Africa, the tiny nation ... everyone lives together in harmony. , But the shimmering ... drug abuse. In fact, it carries a dubious designation: ... in eastern Africa. , “Many youngsters, they know the ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 At the ... held the “RockNRolla Movie Awards” EcoLuxe Lounge, with Choices ... Angeles’ leading producer of sustainable product placement in TV ... of socially conscious and ecologically sound goods and services ... star Chase Masterson hosted the Choices Celebrity Interview Lounge, ...
(Date:4/20/2015)... Connecticut (PRWEB) April 20, 2015 ... Moreen Donahue, DNP, RN, NEA-BC, FAAN who was ... Nursing Education and Research in September 2014, is ... Nursing Officer to lead the development of Western ... this newly created role, Donahue will be responsible ...
(Date:4/20/2015)... 2015 The normal response from the doctor ... we could do.” Especially if the patient sought medical care ... should be much different. So it’s critical the patient’s loved ... be done?” , Not every emergency room physician or ... can be done.” But, according to Ronald P. Benitez ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Says Hello to Yonkers Community with Spa Party 2Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3
... ... wellness. Learn how to improve the look and strength of your abdominal muscles and improve ... on this new Web site. , ... June 17, 2010 -- A new Web site has been developed to help anyone get in ...
... ... to Bring Fresh, Locally Sourced, All-Natural Snacks and Beverages to Kicks 4 Kids Community ... ... First Soccer and the McHenry Area Soccer Federation have partnered with McHenry’s Healthy U ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is a great deal of interest in factors that contribute ... One factor that appears to contribute to the heritable ... codes for the serotonin transporter, also known as the serotonin ... transporter gene appears to increase one,s risk for depression and ...
... role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein ... a robust, non-invasive predictor of cardiovascular (CV) risk in ... by the results of a multinational study presented today ... League Against Rheumatism in Rome, Italy. The presence ...
... Grant to ... Athletes , ... June 17, 2010 -- Athletes for Hope (AFH), an entrepreneurial non-profit founded by 12 of ... purpose of inspiring all athletes to engage in positive social impact, has been awarded a ...
Cached Medicine News:Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 3Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 4Health News:PTSD: The serotonin system influences vulnerability and treatment 2Health News:NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Disposable Cannula Cuffed Tracheostomy Tubes...
Medicine Products: